Market closed
Neuropace/$NPCE
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Neuropace
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all its revenue from the sales of RNS System to hospitals facilities (typically Level 4 CECs) that implant RNS System.
Ticker
$NPCE
Sector
Trading on
Industry
Health Care Equipment & Supplies
Headquarters
Employees
184
Website
Neuropace Metrics
BasicAdvanced
$326M
Market cap
-
P/E ratio
-$0.99
EPS
1.80
Beta
-
Dividend rate
Price and volume
Market cap
$326M
Beta
1.8
52-week high
$18.15
52-week low
$5.45
Average daily volume
85K
Financial strength
Current ratio
5.588
Quick ratio
4.627
Long term debt to equity
729.909
Total debt to equity
748.234
Interest coverage (TTM)
-2.61%
Management effectiveness
Return on assets (TTM)
-14.74%
Return on equity (TTM)
-214.55%
Valuation
Price to revenue (TTM)
4.046
Price to book
33.07
Price to tangible book (TTM)
33.07
Price to free cash flow (TTM)
-18.419
Growth
Revenue change (TTM)
27.00%
Earnings per share change (TTM)
-33.71%
3-year revenue growth (CAGR)
19.38%
3-year earnings per share growth (CAGR)
-29.53%
What the Analysts think about Neuropace
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Neuropace stock.
Neuropace Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Neuropace Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Neuropace News
AllArticlesVideos
NeuroPace to Host Investor Day on January 28th in New York City
GlobeNewsWire·1 day ago
NeuroPace to Showcase the RNS System at the 2024 American Epilepsy Society (AES) Annual Meeting
GlobeNewsWire·1 week ago
NeuroPace Completes Enrollment in Feasibility Study of RNS System for Lennox-Gastaut Syndrome
GlobeNewsWire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Neuropace stock?
Neuropace (NPCE) has a market cap of $326M as of December 14, 2024.
What is the P/E ratio for Neuropace stock?
The price to earnings (P/E) ratio for Neuropace (NPCE) stock is 0 as of December 14, 2024.
Does Neuropace stock pay dividends?
No, Neuropace (NPCE) stock does not pay dividends to its shareholders as of December 14, 2024.
When is the next Neuropace dividend payment date?
Neuropace (NPCE) stock does not pay dividends to its shareholders.
What is the beta indicator for Neuropace?
Neuropace (NPCE) has a beta rating of 1.8. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.